Fundz

Deka Biosciences, Inc. reported raising $15.9 Million in an initial SEC Form D filing, from an offering of $25.9 Million

PRIVATENov 23, 2021$15.9M of $25.9M raised

Amount Raised

$15.9 Million

$15.9 Million sold, per SEC Form D (first sale Nov 23, 2021)

Round Type

Venture

GermantownBiotechnologyHealth CareScience And Engineering

Quick answer

Deka Biosciences, Inc. raised $15.9 Million in a funding round, dated November 23, 2021. Deka Biosciences, Inc. is based in Germantown, Illinois, United States.

How much did Deka Biosciences, Inc. raise?
Deka Biosciences, Inc. raised $15.9 Million in a funding round on November 23, 2021.
What does Deka Biosciences, Inc. do?
Deka is an early-stage biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn's, psoriasis, rheumatoid arthritis and sepsis.
Where is Deka Biosciences, Inc. based and how big is it?
Deka Biosciences, Inc. is based in Germantown, Illinois, United States.
Who are the decision-makers at Deka Biosciences, Inc?
Fundz holds 1 contact at Deka Biosciences, Inc., including the Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Deka Biosciences, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • AN2 Therapeutics raised $80M (Series B) on January 7, 2022.
  • Wheeler Bio raised $14M (Seed) on January 4, 2022.
  • Bond Biosciences raised $6.8M on January 3, 2022.
  • Trait Biosciences Inc. raised an undisclosed amount (Series A) on December 30, 2021.
  • TandemAI raised $25M (Seed) on December 22, 2021.
  • Appili Therapeutics Inc. raised an undisclosed amount (Funding Round) on December 22, 2021.

Who to call at Deka Biosciences, Inc., and when

A new round usually means Deka Biosciences, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Deka Biosciences, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Deka Biosciences, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Deka Biosciences, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Deka Biosciences, Inc.

Location

20271 GOLDENROD LN SUITE 2087

Germantown, Illinois, United States

About

Deka is an early-stage biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn's, psoriasis, rheumatoid arthritis and sepsis. The company is led by serial entrepreneur John Mumm, who is backed by a team of experienced biopharma and CDMO innovators with expertise in drug discovery, product development, characterization and testing. Deka has developed disease specific DiakinesTM that maximize patient benefits through improved pharmacokinetics / pharmacodynamics (PK/PD) function via targeted delivery of dual and complimentary cytokines to affected tissues or cells. Through the use of precision medicine, Deka's vision is to maximize the impact of its DiakineTM therapeutic proteins by ensuring treatment of patients who will best benefit from and respond to our cytokine therapies. To learn more, visit www.dekabiosciences.com. SOURCE Deka Biosciences

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Deka Biosciences, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJohn C., DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Deka Biosciences, Inc.'s next move

See what Strategic adds

Deka Biosciences, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.